Table 1 Baseline characteristics of patients
Variables | HIV patients who completed the ABQ-HIV | HIV patients who did not complete the ABQ-HIV | P-values |
|---|---|---|---|
N | 370 | 25 | |
Age in years – mean (SD) | 51.2 (1.0) | 55.8 (15.5) | 0.031 |
Female gender – n (%) | 58 (15.7%) | 5 (20.0%) | < 0.001 |
Duration since first HIV diagnosis in years – mean (SD) | 11.7 (0.3) | 10.3 (6.1) | 0.466 |
Duration since first HIV treatment in years – mean (SD) | 8.7 (0.2) | 8.6 (5.7) | 0.829 |
Country of origin – n (%) | 0.464 | ||
Germany | 326 (88.1%) | 21 (84.0%) | |
Othera | 41 (11.1%) | 4 (16.0%) | |
Not specified | 3 (0.81%) | 0 (0.0%) | |
Education level – n (%) | 0.622 | ||
No degree | 24 (6.5%) | 3 (12.0%) | |
Apprenticeship | 208 (56.2%) | 17 (68.0%) | |
High school degree | 42 (11.4%) | 2 (8.0%) | |
University degree | 87 (23.5%) | 3 (12.0%) | |
Other | 2 (0.5%) | 0 (0.0%) | |
Not specified | 4 (1.1%) | 0 (0.0%) | |
Employment status – n (%) | 0.167 | ||
Employed | 240 (64.9%) | 14 (56.0%) | |
Unemployed | 45 (12.2%) | 1 (4.0%) | |
Pensioner/other | 81 (21.9%) | 10 (40.0%) | |
Not specified | 2 (0.5%) | 0 (0.0%) | |
Most common treatment regimens – n (%) | |||
Tenofovir alafenamide + emtricitabine + elvitegravir | 65 (17.6%) | 2 (8.0%) | |
Lamivudine + abacavir + dolutegravir | 58 (15.7%) | 4 (16.0%) | |
Tenofovir alafenamide + emtricitabine + rilpivirine | 42 (11.4%) | 0 (0.0%) | |
Tenofovir disoproxil + emtricitabine + efavirenz | 41 (11.1%) | 2 (8.0%) | |
Number of tablets patients needed to take per day (reported by the patient) – n (%) | 0.906 | ||
Not specified | 6 (1.6%) | 2 (8.0%) | |
1–3 | 237 (64.1%) | 14 (56.0%) | |
3–5 | 67 (18.1%) | 4 (16.0%) | |
5–10 | 60 (16.2%) | 5 (20.0%) | |